Company Encyclopedia
View More
name
Cidara Therap
CDTX.US
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials.
1.946 T
CDTX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking191/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-68.70%E
    • Profit Margin0.00%D
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-100.00%E
    • Net Profit YoY-53.01%D
    • Total Assets YoY219.50%A
    • Net Assets YoY265.29%A
  • Cash ScoreD
    • Cash Flow Margin0.00%D
    • OCF YoY-100.00%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio18.56%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cidara Therapeutics (NASDAQ:CDTX) Sets New 1-Year High - Still a Buy?

    Cidara Therapeutics (NASDAQ:CDTX) reached a new 52-week high, trading at $220.74 with significant volume. Analysts have mixed ratings, with a consensus of "Hold" and a price target of $156.11. The company reported a quarterly EPS of ($1.43), missing estimates. Insider and institutional activities show changes in stock positions. Cidara focuses on developing therapies for serious diseases, including fungal infections.

    Market Beat·
    US
    CDTX
    -0.22%
    Market Beat·
    US
    CDTX
    -0.22%

    3,783 Shares in Cidara Therapeutics, Inc. $CDTX Bought by Police & Firemen s Retirement System of New Jersey

    Police & Firemen's Retirement System of New Jersey acquired 3,783 shares of Cidara Therapeutics, valued at $184,000, during the 2nd quarter. Other institutional investors also adjusted their stakes in CDTX. Cidara's stock performance shows a 52-week high of $220.46 and a market cap of $6.91 billion. Analysts have mixed ratings, with a consensus price target of $156.11. Cidara focuses on developing therapies for serious diseases, including fungal infections.

    Market Beat·
    US
    CDTX
    -0.22%
    Market Beat·
    US
    CDTX
    -0.22%

    12:37 ET Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights

    Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws and breaches of fiduciary duties by Gulf Island Fabrication, Movano Inc., Richmond Mutual Bancorporation, and Cidara Therapeutics. Shareholders are urged to contact the firm to discuss their rights and options. The firm may seek increased consideration, additional disclosures, or other relief on behalf of shareholders. Contact Halper Sadeh LLC for more information.

    prnewswire·
    US
    MOVE
    -9.13%
    US
    CDTX
    -0.22%
    US
    GIFI
    +0.17%
    prnewswire·
    US
    MOVE
    -9.13%
    US
    CDTX
    -0.22%
    US
    GIFI
    +0.17%

    HAPPY THANKSGIVING AND EQUITY ALERT: The M&A Class Action Firm Launches Investigation for the Merger - EXAS, SEE, CDTX, and MRSN

    Monteverde & Associates PC is investigating mergers involving Exact Sciences, Sealed Air, Cidara Therapeutics, and Mersana Therapeutics. Shareholders are offered specific cash amounts per share in these deals, and the firm questions their fairness. The firm, known for recovering millions for shareholders, invites concerned shareholders to contact them for more information. The investigation highlights potential concerns over the fairness of these merger deals.

    Acceswire·
    US
    EXAS
    -0.12%
    US
    CDTX
    -0.22%
    Acceswire·
    US
    EXAS
    -0.12%
    US
    CDTX
    -0.22%

    MSD to acquire Cidara after positive phase 2b trial results

    MSD is acquiring Cidara Therapeutics for $9.2 billion after positive phase 2b trial results of CD388, an antiviral for influenza. The trial met all endpoints, highlighting CD388's potential as a breakthrough therapy. hVIVO, a key partner in the drug's development, played a crucial role in the trial's success. The acquisition underscores the importance of hVIVO's expertise in human challenge trials and its diversification into field studies and laboratory services.

    PharmaTimes·
    US
    CDTX
    -0.22%
    PharmaTimes·
    US
    CDTX
    -0.22%
    © 2025 Longbridge｜Disclaimer